bioRxiv
July 2, 2026
Alba Cáceres-Rodríguez, Daniela Iezzi, Olivier Lassalle et al.
preprint
Background Prenatal cannabidiol (CBD) consumption is increasing, driven by a perception of safety relative to Δ9-tetrahydrocannabinol (THC). However, the neurodevelopmental risks of gestational CBD remain largely uncharacterized. Methods Using a sex-disaggregated framework, we investigated adult (P100–140) mouse offspring following in utero exposure (GD5-18; 3 mg/kg) to THC or CBD. Behavioral...
Journal of Neuroendocrinology
July 1, 2026
F. B. Caruso, M. A. Severo, Annalisa Colucci et al.
The aim of this study was to investigate the effects of cannabidiol (CBD) on memory deficits induced by ovariectomy and to directly compare its effects with those of hormone therapy, in order to better understand potential shared mechanisms related to menopause‐associated cognitive decline, with a particular focus on the endocannabinoid system. Three‐month‐old female Wistar rats were randomly...
Drug and Alcohol Dependence
July 1, 2026
Daniel L. Hall, Edward Chesney, Claire Mokrysz et al.
The presence of cannabidiol (CBD) in cannabis may alter cannabinoid pharmacokinetics, however previous research has produced mixed results. Furthermore, no prior research has explored how cannabinoid pharmacokinetics are moderated by age. Using vaporised and inhaled cannabis, we aimed to (1) examine the effect of CBD on the plasma concentration of delta-9-tetrahydrocannabinol (THC) and its...
Frontiers in Pharmacology
June 29, 2026
Laura Gálvez-melero, Sandra Ledesma-Corvi, C. Bis-Humbert et al.
There is a need for characterizing more efficacious therapeutic strategies for glioblastoma multiforme to overcome treatment resistance to the standardized use of temozolomide as well as to better treat its debilitating comorbidities like depression. In this context, combination therapies, particularly cannabidiol with temozolomide exhibited additive or synergistic anti-tumor effects, capable...
Brazilian Journal of Psychiatry
June 16, 2026
Daniel B.a. Prado, Matheus T. Rossignoli, Rafael N. Ruggiero et al.
Objective: Current treatments for schizophrenia (SZ) are often not effective for all symptoms, with sex-dependent effects poorly understood. Cannabidiol (CBD) and sodium nitroprusside (SNP) have emerged as potential prophylactic options. We evaluated their efficacy in preventing positive, negative, and cognitive deficits in a ketamine (KET) rodent model of SZ in both sexes. Methods: Wistar rats...
Physiological research
May 12, 2026
Marcel Bochin, Čestmír Vejmola, Vlastimil Koudelka et al.
Cannabinoids modulate brain network activity, yet the spatial organization and temporal evolution of their electrophysiological effects remain insufficiently characterized in animal models. Here, we investigated how acute oral administration of ?9-tetrahydrocannabinol (THC; 10 mg/kg), cannabidiol (CBD; 10 mg/kg), and their combination influences resting-state EEG dynamics in freely moving rats....
Alcohol and Alcoholism
March 17, 2026
Ieva Poceviciute, Martynas Arbaciauskas, Rokas Buisas et al.
Previous studies have demonstrated that the endocannabinoid system plays a significant role in the development of alcohol use disorder (AUD), and CB1 receptor antagonists/inverse agonists show promise as a novel AUD pharmacotherapy. However, these compounds failed in clinical trials due to the severe psychiatric side effects. Non-psychoactive phytocannabinoids may have a better safety profile...
Biological Psychiatry
March 16, 2026
Xianglian Wang, Jing Xia, Heyi Luo et al.
Ketamine produces rapid antidepressant and antidepressant-like effects in both humans and animal models. However, its therapeutic benefits are tempered by psychoactive side effects, such as hyperlocomotion associated with enhanced dopaminergic activity in the ventral tegmental area (VTA). We tested the therapeutic effect of cannabidiol (CBD) on locomotor activity after systemic (30 mg/kg) or...
Addiction
March 2026
Jack Chung, Daniel Stjepanović, Brandon Cheng et al.
Cannabis use is associated with psychiatric comorbidities, and the use of elta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) produces different neurophysiological and pharmacological effects. This study estimated the strength of associations between vaping of THC and CBD with depressive and anxiety symptoms in adolescents. Observational data were drawn from three years of the nationally...
Journal of Psychopharmacology
March 1, 2026
Eilidh Macnicol, Michelle Kokkinou, Maria Elisa Serrano Navacerrada et al.
2 citations
Cannabis constituents, including Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), show distinct pharmacological profiles with therapeutic relevance for neurological and psychiatric conditions. THC exerts euphoric effects primarily via CB1 receptor activation, while CBD displays non-euphoric properties affecting various pathways. This study evaluated the effects of THC, CBD, and their...